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SUMMARY.-Appreciable insulin occurred in transplants of a hamster and a
mouse adrenal tumour. The hormone was measured by immunoassay. In
hamster experiments, the weight of tumours grown in animals made mildly
diabetic was five times less than those grown in controls. No insulin nor
diabetic effect occurred in transplants of a mouse brain or stomach tumour.
THIS work was done to see iftumours, which arise from specific organs contain
insulin or not and to investigate the effect of diabetes on the growth of such
tumours.
Apart from insulin secreting fibrosoma of mediastinum in hypoglyeaemic
patients (Lowbeer, 1961), there appear to be little assay data on the insulin
content of non-pancreatic tumours. With " generalized animal tumours ",
four teams have reported decreased tumour growth in alloxan diabetic or partially
depancreatized animals, thus indicating a controlling influence of insulin on this
growth (Walker 256 carcinoma: Goranson and Tilser, 1955; Ingle, 1958; Garvie,
1968. Erlich ascites tumour: Jehl et al., 1955). Apart from one paper using the
Novikoff hepatoma (Goranson and Tilser, 1955), there seem to be no publications
about the effect of diabetes on tumours arising from specific tissues. In the
present work hepatomas were not used, since they are so vascular that any
measurement of their insulin content would reflect both tumour and plasma
insulin. As the mammary gland has a high fat content and insulin also affects
fatty acid synthesis, tumours of this gland were not investigated.
MATERIALS AND METHODS
Transplants ofthe following tumours were used:
Hamster adrenal tumour FC/1584/60.-This arose spontaneously in 1960 in a
golden hamster in Dr. F. C. Chesterman's colony (London). It was an adrenal
cortical carcinoma. Non-haemorrhagic and haemorrhagic portions (blood clots)
of this tumour were collected separately. Results (insulin or tumour weight)
refer to the non-haemorrhagic part only.
Mouse adrenal tumour DA.-Foliowing the work of Dickie (1959), 1-2 day old
CE strain mice were ovariectomized. In some animals 9-12 months later a
unilateral adrenal tumour appeared. Only the insulin content of this tumour
was measured.
Mouse brain tumour (Ependymoma A/22).-This appeared in 1948, 354 days
after the implantation of a pellet of 20-methylcholanthrene into the brain
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Mouse gastric adenoma G328.-This appeared in 1949 after 20-methylcholan-
threne had been injected into the wall of the glandular stomach in 1948 (Dr.
H. Stewart, Bethesda, U.S.A.).
For each type, tumour weights and their insulin content were compared in
control animals and in animals which had been treated with a diabetogenic agent,
either one intracardiac (IC) or 3 sub-cutaneous (SC) injections of alloxan (which
destroys pancreatic /8 cells) or anti-insulin serum (AIS: antibodies to ox insulin
raised in guinea-pigs). Tumour transplantation (IP or SC) was always on day 1.
Alloxan diabetes in hamsters and mice was generally induced on day 1, but in
experiment HA3 it was delayed until day 21. The use of AIS in small daily
doses made the animals sub-diabetic. Drops of urine were tested daily or twice
daily forglycosuria onClinistixpaper(AmesandCo.). TakingeachClinistix" + "
as one point, the glycosuric score was kept for each alloxan-treated animal and
these varied considerably. From the daily Clinistix results, graded doses of
globin zinc insulin or protamine zinc insulin were given to prevent highmortality
and yet to try to keep the animals still diabetic. Few ofthe animals were diabetic
by the end of the experiments. Mortality of alloxan-treated hamsters was about
30%, while almost all the AIS hamsters and mice lived. No kidney lesions were
seen at autopsy examination of 10 of our controls, 5 AIS-treated and 10 alloxan-
treated hamsters, though occasionally in the last group there was some hyperaemic
glomerular congestion (Dr. R. Vaughan). Hamster tumours were harvested at
6 or 9 weeks and mouse tumours at 7-8 days or 24-3 weeks.
Tumours were collected in hexane, which was cooled by a cardice-acetone
mixture and were stored at -18° C. Insulin was extracted by homogenizing
and stirring with acid-alcohol. Unwanted protein was removed by precipitation
at pH 8-5, and the insulin then precipitated with an alcohol-ether mixture (Best
et al., 1939; Morgan and Lazarow, 1965). It was dried over P205 in a vacuum
desiccator and stored in this at +20 C. Before assay, the final extract was
ground in a glass pestle and mortar, 0-006 M glycine/HCl buffer (pH 1-2) added
and the solution diluted to the necessary strength using 0 04 M phosphate buffer
(pH 7.4) containing 0.9% saline and 0-025% sodium ethyl mercurithiosalicylate.
Recovery of crude human or rat insulin added to acetone powdered pancreases
ofthe same species was 69% and 80% respectively. A homogenate ofa number of
hamster adrenal tumours was made. Recovery of crude human insulin added to
this was 96%.
Insulin was estimated by Hales and Randle's (1963) radioimmunoassay method
(Type C), using the Radiochemical Centre's (Amersham, Bucks) reagent kit.
The method is based on the competition between labelled and unlabelled (tumour)
insulin to combine with a constant amount of guinea-pig anti-ox insulin serum.
The complex formed is precipitated and counted. The reference standard was
highly purified ox-insulin (six times recrystallized or chromatographically pure
material, 23-8 biologicali.u./g.). This was dissolved inthe same way as thetumour
extract. Our preliminary work on hamster and mouse serum had shown that
insulin from these species could be estimated by these " reagents ". Each
tumour extract was tested at five aliquot levels to check that there was always a
proportionality between insulin found and the level of testing. Thus the calcu-
lation of insulin as milliunits (mu)/g. wet weight was not biased by the level
selected for testing. If the binding power of the anti-ox insulin antibody is poor,
as happened in preliminary work, this can destroy the proportionality relationship.
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Parallel dose-response lines were obtained for the standard preparation and
tumour extracts, while good agreement occurred between duplicate measurements
ofinsulin in the same tumour extract.
RESULTS
Results ofinsulin content and tumour weight are given in Tables I, II and III.
Insulin in adrenal tumours (hamster and mouse): the impedance of adrenal tumour
growth by diabetes (hamster)
Estimations ofinsulin in batches of up to 46 pairs ofnormal hamster adrenals
failed to detect this hormone. When four batches of 80-86 pairs were available,
insulin in quantities of 0-19, 0-17, 0 04 and 0-10 milliunits (mu) ofimmunoreactive
insulin/g. tissue were found. Hamster adrenal tumours (FC/1584/60) from control
animals contained an average of 19 mu/g. wet weight. No insulin or negligible
amounts of the hormone were present in tumours from alloxan or AIS injected
hamsters (Table I).
TABLE I.-Immunoreactive Insulin Content of Hamster and Mouse Adrenal
Tumours, Mouse Brain Tumour and Mouse Stomach Tumour
Tumour insulin (mu/g. wet wt)
No. of estimations Mean i S.E. (range)
A A-A
Alloxan or Alloxan or
AIS treated AIS treated
Type of tumour Control animals Control animals
Hamster adrenal* 1 tumour/estimation
(FC/1584/60) . 4 5 . 18-3±8-3 (2.2-35 4) Negligiblet
5 6 . 18-7±4-3 (9 8-33 7) Negligible
Mouse adrenal (DA) 1 tumour/estimation
1 . 58*5
1 - . 94.4
Mouse brain (A/22) 6-12 tumours/estimation
7 . Negligiblet
1 . 09
1 1 . Negligible Negligible
1 1 . Negligible Negligible
Mouse stomach (G328) 4-12 tumours/estimation
13 - . Negligible
1 1 . Negligible Negligible
1 1 . Negligible Negligible
* The non-haemorrhagic part only of this tumour was estimated.
t Negligible = 0*3-0*02 mu/g. wet wt.
Two mouse DA adrenal tumours contained 58 and 94 mu insulin/g. wet wt
(Table I). Owing to the slow growing nature of the tumour, no mouse diabetic
experiments have been done.
In hamsters, diabetogenic conditions caused a failure of growth in the adrenal
tumour transplants, as indicated by tumour weight. Thus, after six weeks, the
transplants averaged 4-7 times less in weight than those grown in control animals.
This result occurred both in conditions ofsub-diabetes due to daily small injections
of AIS or when alloxan diabetes was used. Expressing the glycosuric score as a
percentage of the possible urinary glucose score, alloxan diabetes caused a 7-46
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(mean of all experiments 25) score. The decreased growth of the tumour
occurred whether the treatment began at the beginning or halfway through the
growth period. Severe diabetes also caused loss of body weight. However, the
decreased tumour growth seemed to be a specific effect of hypoinsulinism because
it occurred in mild or sub-diabetic conditions (see alloxan experiments HA5 and
HA6 and AIS experiments HA7, 8, 9, Table II), where body weight remained
stable. The lower tumour weight of the tumours in experimental hamsters was
always statistically significant. High glycosuric scores tended to be accompanied
by large losses in tumour weight, but this was statistically significant only in
experiment HA2 (Table II).
TABLE II.-Effect ofAlloxan or Anti-insulin Serum on Growth of a Hamster
Adrenal Tumour (FC/1584/60)
No. of Mean gain
hamsters/group in body wtt (g.) Wt oftumourt (g.) ± S.E.
A - A A Ratio of tumour
Expt no. Control Expl Control Expl Control Expl Control/expl
10 mg. alloxan (IC)/100 g. body wt
HAl . 4 5 . 20 9 . 2-140*9 0-5+0 2 . 4-2*
HA2 . 5 6 . 22 10 . 2-1±0-1 0-3±0-1 . 70***
HA3§11 6 11 . 4 -8 . 3-4±1-3 0*7±0 2 . 4.9*
HA4 9 7 . 8 -6 . 2-1±0-4 0*6±0-1 . 3-5*
5 mg. alloxan (IC)/100g. body wt
HA5 . 9 8 . 15 11 . 2-7±0 6 0-6±0-1 . 4-5**
HA6¶ . 5 5 . 27 26 . 3-5±1-2 0 9±0 4 . 3.9*
Anti-insulin serumtt
HA7 . 5 10 . 12 11 . 5-6±0-8 1*0±0*3 . 56***
HA8 . 7 10 . 9 7 . 3-9±1-0 0 8±0-2 50**
HA91I . 7 9 . 9 9 . 3 9±0 9 1 0±0-4 . 39**
*P=<0.05, **P=<90 01, ***P= < 0 001.
t From day 1-day of autopsy.
I Refers to non-haemorrhagic portion of adrenal tumour.
§ Stomach tube feeding with a mixture of powdered pellets and milk.
Alloxan was given on day 21: in other experiments given on day 1, the day of transplantation.
¶ Harvested at 9 weeks: in other HA experiments tumours collected at 6 weeks.
tt AIS was given from days 1-21 in experiments HA7 and HA8 and from days 21-41 in experiment
HA9. Twice daily small doses were used which produced sub-diabetes. Single SC injection dose was
1/17 of one ampoule of K 5205 or Ref. 290365 (Burroughs Wellcome and Co.) for expt HA7 and
1/10,000 of one ampoule MR 51 for experiments HA8 and HA9.
It can be concluded that lack ofinsulin acts specifically to decrease the growth
of hamster adrenal tumour FC/1584/60 and hence the tumour can be regarded
as insulin-dependent.
Absence of insulin in brain and stomach tumours: no diabetic effect on growth of
these tumours
Quantities ofup to 4 g. normal mouse brain or up to 6 g. normalmousestomachs
failed to yield detectable immunoreactive insulin. Nor in estimations using up to
8 g. brain tumour or up to 5 g. stomach tumour obtained from control or experi-
mental animals could insulin be measured (Table I). In three experiments for
each type oftumour, alloxan diabetes did not produce a decrease in tumour weight
over a 3-week period (Table III).
Efforts were made to establish that these results were " true negatives ", i.e.
that the presence of insulin or a diabetic effect were not missed. Quantities of
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TABLE III.-Effect of Alloxan on Growth of a M5oUse Brain Tumour (A/22)
and a Mouse Gastric Tumour (G328)
Mean gain in
Tumour Tumour No. ofmice/group body wt (g.) Wt of tumour (g.) Ratio of
type and harvested ,
A __ tumour wt
expt No. (days) Control Expl Control Expl Control Expl Control/Expl
20 mg. alloxan (SC)/100 g. body wt on day 1
Brain
MB1 21 . 10 14 1 1 . 1*2±0-2 1-8±0-3 0.7*
(Range 0-2)
20 mg. day 1 + 10 mg. day 2 + 10 mg. day 3 of alloxan (SC)/100 g. body wt
Brain
MB2 . 21 . 10 15 1 1 . 1-2±0-2 1-5+0.2 0.8*
10 mg. alloxan (IC)/100 g. body wt on day 1
Brain
MB3 21 . 8 11
(F
7 - 5 mg. alloxan (IC)/100 g. body wt on day 1
-Brain
(Range 0-3)
2 1 . 1-1±0-2 1-8±0'2
Range -2 to +4)
MB4 . 7 . 6 17 . 4 0 . 0 3±0*2 0 2±0 1 .
(Range -4 to +3)
20 mg. day 1 + 10 mg. day 2 + 10 mg. day 3 of alloxan (SC)/100 g. body wt
Gastric
MS1 21 . 9 10 . 2 1 . 0-7±01 0-7±01
(Range 0-3)
10 mg. alloxan (IC)/100 g. body wt on day 1
Gastric
MS2 . 21 . 3 12 . 7 4
(Range 1-9)
Gastric
MS3 21 . 8 7. 2 5
(Range 0-8)
0-*20-1 00-20-1
. 1-2±0-2 1-1±0-3 .
7-5 mg. alloxan (IC)/100 g. body wt on day 1
Gastric
MS4 . 8 . 6 12 . 4 -0-2 . 0-3±0-2 0-2+0-1 .
(Range -3 to +5)
* t test not significant, P = > 0 05.
tissue larger than those in the hamster adrenal experiments were used for insulin
measurements. Sometimes the dose of alloxan was the same in both hamster
adrenal tumour and mouse tumour experiments, i.e. 10 mg. alloxan/100 g. body
wt IC on day 1. The mean glycosuria for the brain tumour experiments was
38 (range 25-57) and for the stomach tumour experiments 28 (range 17-41),
expressed as a percentage of the possible score. Thus even diabetic conditions
more severe than those induced in the hamsters, did not cause tumour weight loss.
In case the later part of the growth in the 21 days experiments had escaped from
the influence ofthe diabetogenic agent given on day 1 or days 1-3 and was masking
a possible diabetic effect in the early stages, mouse and brain tumours were also
collected at 7-8 days. Again, no influence ofdiabetes on tumourweight wasfound.
DISCUSSION
Insulin has been extracted from adrenal tumours by the use of acid-alcohol
and estimated by immunoassay. It is concluded that this insulin is active in the
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used by Best et al. (1939) for his isolation of crude, biologically active insulin, so
the hormone is unlikely to have undergone degradation duringitsextraction. The
immunoassay is regarded as having a high specificity for insulin. Parallelism
occurred between the results obtained in ourimmunoassays with aliquotsoftumour
extracts and with aliquots of standard highly purified insulin, known to have
biological activity. This would indicate a lack of inhibitors and exclude the
presence of interfering substances giving false positives in the tumour extracts.
Steiner and his colleagues (Rubenstein, Steiner, SoojaCho, Lawrence andKirsteins,
1969) have found pro-insulin, precursor of insulin, present in weak concentrations
in acid-alcohol extractions of bovine pancreas. This has about 20% of the
biological activity of insulin and is able to react with some guinea-pig anti-bovine
insulin sera. However, pro-insulin is converted to insulin in the islets with an
in vitro half-life of about 1 hour. Final confirmation of our immunoassay results
is given in the diabetes experiments. It has been demonstrated that insulin is
important to the growth of the hamster adrenal tumour since diabetes impedes
that growth. Conversely, there can be no effective insulin acting on the growth
of the brain and stomach tumours investigated, since these are not affected by
diabetes.
While the concentration ofinsulin is much lower in the hamster adrenal tumour
than in the hamster pancreas (2-1 mu/g. wet wt; Sodoyez, et al., 1968), the hamster
adrenal tumour contained 19 mu/g. wet wt and the mouse between 58-94 mu/g.
compared to 72 mu/g. in a pancreatic islet cell tumour (No. 2309) found in a male
golden hamster treated with a 30 mg pellet of testosterone proportionate (Sodoyez
et at., 1967). The insulin would either have been produced by the adrenal or
concentrated by it from the blood. Its biosynthesis has not yet been investigated
but the tumour insulin level is about 103 greater than the nomal plasma levels.
No experiments on the possible steroid production of the tumour have been
made.
Thirteen cases of human adrenal tumour associated with hypoglyeaemia have
been recorded (Symington, personal communication), so it is possible these produce
insulin. Our finding of insulin in adrenal tumours of both mouse and hamster
suggest it may be a characteristic of rodent adrenal tumours or of one type of
adrenal tumour. Presumably there may be an alteration in adrenal glucose
metabolism in the tumour-bearing animals. It may be pointed out thatthenormal
adrenal gland utilized glucose both by glycolysis and via the hexose monophate
(HMP) pathway (pentose shunt) (Dickens, 1955; Glock and McLean, 1954). The
importance of the latter in tumour FC/1584/60 has not yet been investigated.
Other workers have reported that the HMP pathway is under the control of
insulin (Glock and McLean, 1954; Young, 1962; Beloff-Chain et al., 1959), and that
it is important in the metabolism of some " generalized tumours " (Beaconsfield
and Liuzzi, 1963; Glock and McLean, 1954; Wenner and Weinhouse 1956;
Sahasrabude, 1958; Sahasrabude et al., 1960).
Negative results for the present of insulin and the effect of diabetes were
obtained for mouse ependymoma A/22 and mouse stomach tumour G328. It
would be interesting also to work on brain tumours arising from other neuroglial
tissue, i.e. gliomas or astrocytomas. Also the present brain and stomach tumours
have been passaged for about 20 years, so it would be preferable to continue work
with recently induced tumours. Details of any " organ specific " tumours in
hamsters or mice obtained by other workers would be most gratefully received.
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